Risperidone for bipolar disorders

References

• Risperidone (Risperdal®) product information. Janssen Pharmaceutical Products, NJ, USA (2003).
   Google Scholar
• Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch. Gen. Psych. 50(2), 85–94 (1993).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Calabrese JR, Weissman MM et al. Screening for bipolar disorder in the community. J. Clin. Psychiatry 64(1), 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch. Gen. Psych. 48(1), 62–68 (1991).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 271(23), 918–924 (1994).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18–month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64(9), 1013–1024 (2003).
   PubMed Web of Science ®Google Scholar
• Bowden C, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psych. 60(4), 392–400 (2003).
   Google Scholar
• Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J. Clin. Psychiatry 65(Suppl. 10), 28–35 (2004).
   PubMed Web of Science ®Google Scholar
• Zyprexa Prescribing Information. Eli Lilly and Company, IN, USA (2004).
   Google Scholar
• Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55(Suppl.), 5–12 (1994).
   PubMed Web of Science ®Google Scholar
• Kalkman HO, Loetscher E. α2C-adrenoceptor blockade by clozapine and other antipsychotic drugs. Eur. J. Pharmacol. 462(1–3), 33–40 (2003).
   PubMed Web of Science ®Google Scholar
• Pania L, Gessab GL. Dopaminergic deficit and mood disorders. Int. Clin. Psychopharmacol. 17(Suppl. 4), S1–S7 (2002).
   Web of Science ®Google Scholar
• Hirschfeld RM, Keck PE Jr, Kramer M et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am. J. Psychiatry 161(6), 1057–1065 (2004).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (Revision). American Psychiatric Press, Washington DC, USA (2002).
   Google Scholar
• Sajatovic M, Blow FC, Ignacio RV, Kales HC. Age-related modifiers of clinical presentation and health service use among veterans with bipolar disorder. Psychiatr. Serv. 55(9), 1014–1021 (2004).
   PubMed Web of Science ®Google Scholar
• Lasser RA, Ramstack JM, Grandolfi GP, Mannaert E, Hoore PD. Long-acting injectable risperidone (Risperdal®Consta): manufactured using medisorb® microsphere technology, pharmacokinetics, and injection site assessments. Presented at the International Congress of Schizophrenia Research. CO, USA, March 29 – April 2 (2003).
   Google Scholar
• Package Insert. Risperdal® Consta (risperidone). Janssen Pharmaceutical Products, NJ, USA (2003).
   Google Scholar
• Ravindran A, Silverstone P, Lacroix D, van Schaick E, Vermeulen A, Alexander J. Risperdone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Clin. Pharmacokinet. 43(11), 733–740 (2004).
   PubMed Web of Science ®Google Scholar
• Bozikas V, Petrikis P, Karavatos A. Urinary retention caused after fluoxetine-risperidone combination. J. Psychopharmacol. 15(2), 142–143 (2001).
   PubMedGoogle Scholar
• Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia A. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther. Drug Monit. 23(3), 223–227 (2001).
   PubMed Web of Science ®Google Scholar
• Khanna S, Vieta E, Lyons B et al. Risperidone monotherapy in acute bipolar mania (Poster). Fifth International conference on bipolar disorder (ICBD), Pittsburgh, PA, USA (2003).
   Google Scholar
• Smulevich AB, Khanna S, Eedekens M. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol European Neuropsychopharmacology 15, 75–84 (2005)
   Google Scholar
• Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind, randomized controlled trial. Clin. Neuropharmacol. 21(3), 176–180 (1998).
   PubMed Web of Science ®Google Scholar
• Vieta E, Bruge E, Goikolea JM et al. Acute and continuation risperidone montherapy in mania. Human Psychopharmacology 19(1), 41–45 (2004)
   PubMed Web of Science ®Google Scholar
• Hirschfeld R, Vornic, Ksarcher K et al. Risperidone monotherapy in acute bipolar mania: a 9-week extension trial. New research poster presented at the American College of Neruopsychopharmacology 42nd Annual Meeting (ACNP). San Juan, Puerto Rico (2003)
   Google Scholar
• Licht RW, Bysted M, Christensen H. Fixed-dose risperidone in mania: an open experimental trial. Int. Clin. Psychopharmacol. 16(2), 103–110 (2001).
   PubMedGoogle Scholar
• Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br. J. Psychiatry 182, 141–147 (2003).
   PubMed Web of Science ®Google Scholar
• Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry 159(7), 1146–1154 (2002).
   PubMed Web of Science ®Google Scholar
• Petrie W. Risperidone versus olanzapine as adjunctive therapy in the treatment of patients with bipolar disorder who are recieivng a primary thymoleptic agent. American Psychiatric Association 157th Annual Meeting. NY, USA, May 1–6 (2004).
   Google Scholar
• Vieta E, Herraiz M, Parramon G, Goikolea JM, Fernandez A, Benabarre A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J. Affect. Disord. 72(1), 15–19 (2002).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Myers JE, Grossman F, Xie Y. Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder. J. Clin. Psychiatry 65(5), 707–714 (2004).
   PubMed Web of Science ®Google Scholar
• Yatham LN, Binder C, Riccardelli et al. Risperidone in acute and continuation treatment of mania. Int. Clin. Psychopharmacol. 18(4), 227–235 (2003)
   PubMed Web of Science ®Google Scholar
• Vieta E, Goikolea JM, Corbella B et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J. Clin. Psychiatry 62(10), 818–825 (2001).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Shelton RC. Risperidone with and withour paroxetine compared to paroxetine alone for bipolar depression. 41st Annual meeting of the American College of Neuropsychopharmacology (ACNP). Hawaii, USA (2001).
   Google Scholar
• McIntyre RS, Mancini DA, Srinivasan J, McCann S, Konarski JZ, Kennedy SH. The antidepressant effects of risperidone and olanzapine in bipolar disorder. Can. J. Clin. Pharmacol. 11(2), e218–e226 (2004).
   PubMedGoogle Scholar
• Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J. Clin. Psychiatry 65(12) 1715–1719 (2004).
   PubMedGoogle Scholar
• American Diabetes Association; America Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27(2), 596–601 (2004).
   PubMed Web of Science ®Google Scholar
• Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry 61(9), 638–642 (2000).
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Hsu DJ, Rosenquist KJ, Katzow JJ, Goodwin FK. Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann. Clin. Psychiatry 16(2), 69–73 (2004).
   PubMedGoogle Scholar
• Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry 159(1), 133–135 (2002).
   PubMed Web of Science ®Google Scholar
• Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D. Differential effects of antipsychotic agents on the risk of development of Type 2 diabetes mellitus in patients with mood disorders. Clin. Ther. 25(4), 1150–1171 (2003).
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Volavka J et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry 160(2), 290–296 (2003).
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J. Clin. Psychiatry 63(2), 120–125 (2002).
   PubMed Web of Science ®Google Scholar
• Zarate CA, Quiroz JA. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord. 5(3), 217–225 (2003).
   PubMed Web of Science ®Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (DSM-IV-TR). American Psychiatric Press, Washington DC, USA (2000).
   Google Scholar
• Gelenberg AJ, Pies R. Matching the bipolar patient and the mood stabilizer. Ann. Clin. Psychiatry 15(3–4), 203–216 (2003).
   PubMedGoogle Scholar
• Keith SJ, Pani L, Nick B. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr. Serv. 55(9), 997–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E. Treatment adherence in bipolar patients. Clin. Approaches Bipolar Dis. 1(2), 49–56 (2002).
   Google Scholar
• Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psych. 48(12), 1082–1088 (1991).
   PubMed Web of Science ®Google Scholar
• Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr. Scand. 101(2), 119–124 (2000).
   PubMed Web of Science ®Google Scholar
• Muller-Oerlinghausen B, Muser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J. Affect. Disord. 25(4), 261–269 (1992).
   PubMed Web of Science ®Google Scholar